Noetik's core thesis is that the 95% failure rate in cancer trials isn't due to bad drug design, but an inability to identify the correct patient sub-population. Their models aim to solve this patient selection problem from the outset, rescuing potentially effective drugs.

K-36's epigenetic drug focuses on reversing the malignant programming of cancer cells. This approach aims to resensitize tumors to other treatments, making combination therapies the core strategy for achieving more durable responses, rather than relying on monotherapy to kill cells directly.

To reduce risk, Nuago prioritizes cancers based on two criteria: high unmet medical need and the existence of clinically validated delivery methods for that specific tissue. This strategy separates their novel drug science from novel delivery science, allowing them to focus resources on proving their mechanism without inventing a delivery system.

The standard approach to reducing cancer drug toxicity is narrowing the target to specific mutations (e.g., HER2, KRAS). While this improves safety, it drastically shrinks the addressable patient population for each new therapy. This puts immense pressure on the pharmaceutical business model, where development costs average $2.5 billion per drug.

For a small biotech, demonstrating that a drug is both clinically active on its own and well-tolerated is the most critical step. This de-risks the asset and opens the door to lucrative combination therapy partnerships with large pharma companies, as it minimizes the risk of combined toxicity killing the trial.

Diakonos chose glioblastoma, the deadliest brain cancer, for its first trial. This counterintuitive strategy provided a faster data readout, powerful validation upon success, and a lower regulatory burden from the FDA—all critical advantages for an early-stage company.

Instead of analyzing a broad patient population, Yellowstone focuses on a hyper-specific cohort: 15 out of 2,000 AML patients who were not only cured by stem cell transplants but also experienced no immune toxicity. This "elite responder" approach aims to identify therapeutic targets that are inherently both effective and safe, learning directly from ideal human outcomes.

Step Pharma's confidence in their drug's clean safety profile originated from studying a human population with a natural mutation in the CTPS1 gene. This real-world genetic data de-risked their therapeutic approach from the outset, guiding development towards a highly selective and safe inhibitor.

K-36's target, NSD2, can both initiate certain cancers (a founding driver) and help other cancers survive treatment pressure (a dependency). This dual role makes it a highly valuable target because it is relevant across different stages and types of cancer, justifying building an entire company around it.